ArticleFrontiers in pharmacology2025
EPA-lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Echocardiographic assessment and new advances of right ventricle function in rats with pulmonary hypertension.Frontiers in pharmacology · 2025Review
- Macrophage-driven immunopathology in pulmonary arterial hypertension: from mechanisms to targeted therapies.Frontiers in immunology · 2025Review
- Pulmonary hypertension: etiology and anti-inflammatory treatment pathways of natural products.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary arterial hypertension (PAH) is a progressive pulmonary arteriopathy characterized by vascular remodeling and subsequent increases in pulmonary vascular resistance, which further develops into right ventricular failure and death. Currently, PAH management targets pulmonary vasoconstriction, though there is an unmet medical need to develop therapeutics focusing on pulmonary vascular remodeling. Recently, we reported that 5,6-diHETE lactone (EPA-L, a stable metabolite of the EPA fatty acid) elicits vasodilation and blood-pressure-lowering effect in 5/6 nephrectomy hypertensive rats and vasodilation in human arterioles by an endothelial-dependent mechanism. Aim: We aimed to investigate the effect of EPA-L in a monocrotaline (MCT)-induced rat model of PAH. Methods: Sprague-Dawley Rats were divided into four groups; 3 received MCT (60 mg/kg, s. c.), and the control group was treated with saline. After 3 weeks, MCT rats were treated with saline, 0.3 or 3.0 mg/kg EPA-L, for five consecutive days. Finally, all animals were sacrificed upon functional, hematological, and histological evaluations. Results: EPA-L administration (i.v.) significantly reduced mean pulmonary arterial pressure (p < 0.05), echocardiographic pulmonary artery time-to-peak (p < 0.05), arterioles intimal-media thickness (p < 0.05) compared to the MCT group. Blood chemistry resulted in a significant reduction in hypoxic indices following the EPA-L administration, but it did not reduce the macrophage infiltration to the lungs and indicators of systemic inflammation, such as neutrophil count and % lymphocyte. Conclusion: In addition to the dilation properties, EPA-L attenuates MCT-induced pulmonary hypertension by improving hemodynamic parameters, and vascular modification. Therefore, EPA-L may act as a promising candidate for treating PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.